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E3 ubiquitin ligases LNX1 and 
LNX2 are major regulators of the 
presynaptic glycine transporter 
GlyT2
A. de la Rocha-Muñoz1,2,5, E. Núñez1,2,5, E. Arribas-González3,5, B. López-Corcuera1,2, 
C. Aragón1,2* & J. de Juan-Sanz4*
The neuronal glycine transporter GlyT2 is an essential regulator of glycinergic neurotransmission 
that recaptures glycine in presynaptic terminals to facilitate transmitter packaging in synaptic 
vesicles. Alterations in GlyT2 expression or activity result in lower cytosolic glycine levels, emptying 
glycinergic synaptic vesicles and impairing neurotransmission. Lack of glycinergic neurotransmission 
caused by GlyT2 loss-of-function mutations results in Hyperekplexia, a rare neurological disease 
characterized by generalized stiffness and motor alterations that may cause sudden infant death. 
Although the importance of GlyT2 in pathology is known, how this transporter is regulated at the 
molecular level is poorly understood, limiting current therapeutic strategies. Guided by an unbiased 
screening, we discovered that E3 ubiquitin ligase Ligand of Numb proteins X1/2 (LNX1/2) modulate 
the ubiquitination status of GlyT2. The N-terminal RING-finger domain of LNX1/2 ubiquitinates a 
cytoplasmic C-terminal lysine cluster in GlyT2 (K751, K773, K787 and K791), and this process regulates 
the expression levels and transport activity of GlyT2. The genetic deletion of endogenous LNX2 in spinal 
cord primary neurons causes an increase in GlyT2 expression and we find that LNX2 is required for 
PKC-mediated control of GlyT2 transport. This work identifies, to our knowledge, the first E3 ubiquitin-
ligases acting on GlyT2, revealing a novel molecular mechanism that controls presynaptic glycine 
availability. Providing a better understanding of the molecular regulation of GlyT2 may help future 
investigations into the molecular basis of human disease states caused by dysfunctional glycinergic 
neurotransmission, such as hyperekplexia and chronic pain.
Glycine acts as an inhibitory neurotransmitter in the central nervous system (CNS), playing a fundamental role in 
neuronal circuits of the central auditory pathway, receptive fields in the retina and spinal cord sensitive pathways. 
Glycinergic neurotransmission strength is controlled presynaptically by the activity of a surface glycine trans-
porter, GlyT2, which recaptures glycine back to the presynaptic terminal to refill synaptic vesicles. Alterations in 
GlyT2 expression or activity result in the emptying of synaptic vesicles, which vastly weakens glycinergic neu-
rotransmission1–3. In humans, this dysfunction is the main presynaptic cause of Hyperekplexia4–6 but may also 
be involved in the pathology of chronic pain7 and deficits in auditory processing8. Although the importance 
of GlyT2-mediated glycine transport in pathology is known2,6,9 and some regulatory mechanisms of this neu-
ronal transporter have been described, a deeper understanding the molecular regulation of GlyT2 would provide 
insight into the molecular and cellular basis of glycinergic neurotransmission and potentially lead to identifying 
new therapeutic targets for Hyperekplexia or chronic pain. Previous studies on GlyT2 regulatory mechanisms 
revealed that GlyT2 activity is regulated by PKC activation10,11, P2Y and P2X purinergic receptors12,13 and direct 
interaction with several proteins14–18 including Na+/K+-ATPase19 and PMCAs20.
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In addition, we previously described that GlyT2 trafficking and surface expression are regulated by ubiquit-
ination11,21, a process in which the small protein ubiquitin is covalently attached to a cytoplasmic lysine residue 
of a target protein. Protein ubiquitination is a versatile regulatory post-translational modification that controls 
intracellular signaling events essential for neuronal function and synapse integrity, including trafficking and 
turnover of presynaptic proteins22–24. The enzymatic cascade catalyzing ubiquitination of any substrate com-
prises the sequential activity of the E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme and E3 
ubiquitin-ligase. E3s are essential for the reaction, as they present a dual role as molecular matchmakers and cat-
alysts to provide efficiency and specificity to the reaction25–27. However, despite the importance of ubiquitination 
in modulating GlyT2-mediated recapture of glycine, the molecular identity of E3 ligase controlling this process 
remains unknown.
The LNX (Ligand of NUMB Protein-X) protein family is a family of E3 ubiquitin ligases characterized by 
the presence of a RING domain and one to four PDZ domains28. LNX1 and LNX2, two of the five members 
of the family, are expressed in neurons and other cell types in the nervous system28 and present high struc-
tural homology with one RING and four consecutive PDZ domains (Fig. 1A). These PDZ domains promote the 
interaction with many neuronal substrates such as NUMB28, c-Src29 or PKCα30, as well as the presynaptic active 
zone proteins CAST31, ERC1, ERC2 and LIPRIN-αs32, which has led to suggest that LNX1/2 may modulate syn-
apse maturation and neurotransmission33,34. To better understand the modulatory roles of LNX1/2 in neurons 
and other cell types, previous efforts in the field took advantage of unbiased proteomic screening approaches to 
identify potential interactors of each of the PDZ domains32,35–37. The second PDZ domain of LNX1/2 (PDZ2) is 
a class I PDZ domain that binds C-terminal motifs with the sequence S/T-X-C35, a compatible sequence with 
the highly conserved PDZ binding motif existing in the C-terminus of GlyT2 (sequence TQC, see Fig. 1B). A 
previous proteomic study unbiasedly identified the possibility of an interaction between LNX1 and GlyT235, 
although no validation or functional studies were pursued after the initial proteomic identification. Given the 
importance of GlyT2 in the control of inhibitory glycinergic neurotransmission and that ubiquitination is an 
essential post-translational modification that regulates its function and expression, we decided to explore whether 
LNX1 and the homologous LNX2 are presynaptic E3-ligases that control GlyT2 activity.
In this work, we demonstrate that GlyT2 interacts with and it is ubiquitinated by LNX1 and LNX2 (LNX1/2). 
LNX1/2 overexpression reduces the expression of GlyT2, impairing glycine transport. Mutations in the 
C-terminal lysine cluster of GlyT2 prevent both ubiquitination and effects on GlyT2 activity induced by wild 
type LNX1/2, indicating that the last 4 lysines are necessary for the modulatory function of LNX1/2 onto GlyT2. 
Contrarily to the effects observed in overexpression experiments, genetic ablation of LNX2 by shRNA in primary 
spinal cord neurons caused an increase in the expression of GlyT2, indicating the existence of a constitutive regu-
lation of the transporter by LNX2 activity in glycinergic neurons. Previous studies identified that PKC activation 
resulted in increased GlyT2 ubiquitination and decreased expression10,11,21. Here we show that ablation of LNX2 
in spinal cord neurons abolished the effect of PKC on the expression of GlyT2, suggesting that PKC is a key con-
troller of LNX1/2 activity and its effect on GlyT2 expression. Taken together, these findings indicate that LNX1/2 
can modulate presynaptic glycine recapture by regulating GlyT2 ubiquitination levels and expression, suggesting 
that these proteins may play a role in controlling inhibitory glycinergic neurotransmission strength in the CNS.
Figure 1. Schematic diagram of the modular domain structure of LNX1/2 proteins and sequence alignment of 
GlyT2 C-terminal region from different species. (A) Graphic scheme showing the two main isoforms of LNX1, 
p70 (short isoform) and p80 (long isoform with RING domain) and LNX2. A previous unbiased screening 
effort by Guo et al.35 identified the last 8 amino acids of GlyT2 (DLELGTQC) as a possible interacting peptide 
for the PDZ II domain of LNX, which recognizes the consensus sequence –[S/T]-X-C*, where * shows the end 
of the protein. (B) Multiple sequence alignment of rat GlyT2 C-terminal region 791–799 from different species. 
Identical conserved PDZ binding motif (PBM) from different species are shown in bold.
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Results
LNX1 p80 and p70 isoforms interact with GlyT2. To explore whether LNX1/2 could be E3 ligases for 
GlyT2, we began by exploring the physical and functional relationship between LNX1 and GlyT2. First, to study 
whether LNX1 and GlyT2 interact in heterologous cells, we transfected COS7 cells with GlyT2 and FLAG-tagged 
LNX1-p80 isoform (LNX1-p80, the longest LNX1 isoform; see Fig. 1A), and used coimmunoprecipitation assays 
to detect protein interaction. Immunoprecipitation of GlyT2 resulted in coimmunoprecipitation of FLAG-tagged 
LNX1-p80 (Fig. 2A, second lane), and correspondingly, immunoprecipitation of FLAG-tagged LNX1-p80 coim-
munoprecipitated GlyT2 (Fig. 2A, third lane). We also explored whether LNX1-p70, a shorter isoform with no E3 
ligase activity (Fig. 1A), interacts with GlyT2, as this isoform also contains the PDZ2 domain that was predicted 
to bind the transporter. Using the same approach, we observed that immunoprecipitation of GlyT2 resulted in 
coimmunoprecipitation of Myc-tagged LNX1-p70 (Fig. 2B, second lane), and correspondingly, immunoprecipi-
tation of Myc-tagged LNX1-p70coimmunoprecipitated GlyT2 (Fig. 2B, third lane; see high exposure). These data 
indicate that the previously identified interaction between the PDZ2 domain of LNX1 and a purified peptide with 
the sequence of the last 8 amino acids of GlyT235 does in fact occur between full-length GlyT2 and LNX1 in a 
cellular environment.
Ubiquitin ligase activity of LNX1 regulates GlyT2 expression and function. We next hypothesized 
that the observed LNX1-GlyT2 interaction may occur to control the ubiquitination state of GlyT2. We assayed 
whether LNX1 ubiquitinates GlyT2 in cells by co-transfecting HA-tagged ubiquitin and GlyT2 with or without 
overexpressing wild type LNX1-p80 in COS7 cells. We immunoprecipitated GlyT2 from cell lysates and measured 
its ubiquitination levels by immunoblotting with an anti-HA antibody, normalizing HA immunodetection against 
the immunoprecipitated amount of GlyT2 in each case to control for variability on GlyT2 expression. Compared 
to the control (Fig. 2C lane 1), an increased ubiquitination signal was found when LNX1-p80 was overexpressed 
(Fig. 2C, lane 2) showing that increased levels of LNX1 indeed promote GlyT2 ubiquitination. These experiments 
also show that GlyT2 expression levels are drastically reduced when LNX1-p80 is overexpressed (Fig. 2C lower 
blot; discussed in next paragraph). Quantification of these data indicated that overexpression of LNX1 signifi-
cantly increased GlyT2 ubiquitination levels by ~2 fold (Fig. 2D, n = 13, *p = 0.011GlyT2). Next, we explored 
whether this process requires a cytoplasmic C-terminal lysine cluster in GlyT2 that has been previously demon-
strated to control its ubiquitination and expression21. Using the same approach, we expressed a mutant in which 
this cluster of lysines have been mutated to arginines to impair their ubiquitination (GlyT2-4KR) with or without 
LNX1-p80 and we found no significant differences in ubiquitination levels of GlyT2-4KR when LNX1-p80 was 
overexpressed (Fig. 2C, lane 4; n = 5, n.s., not significantly different). These results indicate that LNX1-p80 ubiq-
uitinates the C-terminal lysine cluster of GlyT2.
Our ubiquitination experiments did not find single bands corresponding to monoubiquitinated GlyT2 forms 
but showed a typical smear pattern that likely corresponds to polyubiquitinated forms38,39. Whereas monoubiq-
uitination in general may regulate location and activity of diverse cellular proteins40, polyubiquitination is the 
type of ubiquitin modification that can target proteins for degradation41. We noticed that in our ubiquitination 
experiments overexpression of LNX1-p80 induced a significant reduction in GlyT2 expression levels, suggesting 
that ubiquitination of GlyT2 by LNX1 regulates the expression of the transporter, similarly to what it does with 
other proteins35,42–46. Results from Fig. 2E,F showed that co-expression of LNX1-p80 and GlyT2 resulted in a 
significant reduction of ~60% in the levels of GlyT2 (n = 10, ***p = 1 · 10−4) but no variation in the expression 
of GlyT2-4KR was detected. These results indicate that LNX1 can only control GlyT2 expression if the cyto-
plasmic C-terminal lysine cluster in GlyT2 remains intact, confirming that LNX1 promotes ubiquitination of 
those particular residues to control GlyT2 expression. To understand the functional relevance of LNX1-mediated 
control of GlyT2 expression, we next explored to what extent LNX1 expression impacts glycine recapture using 
[3H]-glycine uptake assays in COS7 cells. Glycine transport by GlyT2 is essential for maintaining diverse aspects 
of motor function and impairment of its activity causes important pathologies in humans, from movement dis-
orders to sensory dysfunctions9. We observed that co-expression of wild-type LNX1-p80 with GlyT2 resulted in 
a significant reduction of glycine transport of ~40% (Fig. 2G, n(GlyT2 control) = 43, n(GlyT2- LNX1-p80) = 27; 
****p < 1 · 10−4). Contrarily to wild type GlyT2, transport activity of GlyT2-4KR remained unaffected with 
LNX1-p80 overexpression (Fig. 2G, right, n(GlyT2-4KR control) = 16, n (GlyT2-4KR-LNX1-p80) = 16), indi-
cating that LNX1-p80 alters the transport activity of GlyT2 by reducing the expression of the transporter. Taken 
together, these results indicate that LNX1-p80 induces ubiquitination of the C-terminal lysine cluster of GlyT2 
and this process regulates the expression levels and transport activity of GlyT2.
LNX2 also interacts with GlyT2 to control its ubiquitination and expression. LNX2 pre-
sents high structural homology to the largest isoform of LNX1, LNX1-p80 (Fig. 1A). Given that many inter-
actors of the PDZ2 domains of LNX1 and LNX2 are shared between both proteins28,30,33, we next explored 
whether LNX2 could also act as a regulator of GlyT2 activity. We followed a similar approach to the one fol-
lowed for LNX1. First, using coimmunoprecipitation assays performed in COS7 cells expressing GlyT2 and 
Myc-tagged LNX2 we confirmed that both proteins interact, as the immunoprecipitation of GlyT2 resulted 
in coimmunoprecipitation of Myc-tagged LNX2 (Fig. 3A, lane 2), and correspondingly, immunoprecipita-
tion of Myc-tagged LNX2 coimmunoprecipitated GlyT2 (Fig. 3A, lane 3). Next, we performed ubiquitination 
assays as before. GlyT2 was immunoprecipitated from cell lysates and its level of ubiquitination was ana-
lyzed by immunoblotting with an anti-ubiquitin antibody (Fig. 3B). Compared to the control (Fig. 3B lane 1) 
an increased ubiquitination signal was measured 24 h after transfection when LNX2 was overexpressed 
(Fig. 3B lane 2) and quantification of these data indicated that LNX2 significantly increased GlyT2 ubiq-
uitination levels by ~1.5 fold (Fig. 3C, n = 6; **p = 0.022). Consistent with the idea that LNX2 functions 
as E3 ubiquitin ligase26, we observed that co-expression of Myc-LNX2 with GlyT2 resulted in a significant 
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Figure 2. The interaction of LNX1 with GlyT2 controls the functional expression of the transporter. (A,B) 
COS7 cells lysates expressing GlyT2 and FLAG-p80LNX1 (A) or Myc-p70LNX1 (B) were subjected to 
immunoprecipitation against GlyT2 and FLAG or Myc, showing that GlyT2 coimmunoprecipitates both 
LNX1-p70 (B, middle lane) and LNX1-p80 (A, middle lane). Correspondingly, LNX1-p70 and LNX1-p80 
coimmunoprecipitate GlyT2 (A,B, right lane). A higher exposure is shown in the case of p70 to observe GlyT2 
in Myc-LNX1-p70 immunoprecipitates. C) COS7 cells were transiently transfected with GlyT2 or GlyT2-4KR, 
HA-tagged ubiquitin and with or without FLAG-LNX1-p80. GlyT2 was immunoprecipitated and ubiquitination 
of the transporter was assayed by immunoblotting against HA. Blots were probed against GlyT2 to normalize 
ubiquitination signal against the amount of GlyT2 immunoprecipitated in each case to correct for GlyT2 
protein expression. (D) Quantification of GlyT2 ubiquitination normalized to the control (no transfection of 
LNX1). *p = 0.011, n.s., not significantly different, using Kruskall-Wallis with Dunn’s post hoc test. Number 
of experiments in each case: n(GlyT2 control) = 13, n(GlyT2-p80) = 13, n(GlyT2-4KR control) = 4, n(GlyT2-
4KR-p80) = 4. Blots used in this figure are obtained from different gels, and cropped results are presented for 
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reduction of ~60% in the level of GlyT2 and a negligible variation in GlyT2-4KR expression (Fig. 3D,E n(G-
lyT2 control) = 8, n(GlyT2 + LNX2) = 8, n(GlyT2-4KR) = 4, n (GlyT2-4KR + LNX2) = 4; ****p < 1 · 10−4). 
However, we also observed that despite both LNX1 and LNX2 ubiquitinate GlyT2 to control its expression, LNX2 
effects appeared to be slower and degradation of the transporter was only seen after 48 h of overexpression of the 
ubiquitin ligase (Fig. 3D,E shows expression at 48 h; for no effect at 24 h see blot for GlyT2 in Fig. 3B). Lastly, we 
confirmed that LNX2 activity can impact glycine recapture using [3H]-glycine transport assays. GlyT2 transport 
activity showed a decrease of ~40% when LNX2 was overexpressed (Fig. 3F) n(control) = 27, n(LNX2) = 27. 
****p < 1 · 10−4. Thus, these results confirm that the E3 ubiquitin ligase LNX2 interacts with GlyT2 to modulate 
its expression and function through ubiquitination.
Ablating LNX2 in neurons increases the expression of endogenous GlyT2. We next decided 
to explore whether neuronal GlyT2 is modulated by endogenous LNX proteins. We first measured the 
expression of LNX1 and LNX2 using qPCR in primary cultures of brainstem and spinal cord, in which 
GlyT2 is strongly expressed. Relative mRNA levels of LNX proteins were quantified and normalized using 
glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH, see experimental procedures). Although the mRNA of 
LNX2 was easily detectable, we could not detect the mRNA of LNX1-p80 in DIV12 primary neurons (Fig. 4A). 
LNX1 is strongly expressed in neuronal stem cells47 but it expression is known to decay in differentiated neu-
rons28,46. To confirm that the lack of detection of LNX1-p80 in our cultures was not due to a technical issue, we 
verified that our probes could easily detect the mRNA of p80-LNX1 in renal tissue, as previously published28 (not 
shown). Because of the apparent scarce or undetectable presence of the catalytically active isoform LNX1-p80 in 
our system we decided to only explore the role of endogenous LNX2 in controlling GlyT2. To do this, we ablated 
the expression of LNX2 using a viral knockdown approach in primary neurons that reduced LNX2 mRNA by 
80% after 11 days of infection when compared to neurons infected with a scrambled shRNA (Fig. 4B). Notably, in 
these conditions ablating the function of LNX2 resulted in a significant increase of endogenous GlyT2 expression 
(Fig. 4C,D; n = 6; ****p < 1 · 10−4). This supports our initial experiments in heterologous cells as in these, over-
expression of LNX2 causes a decrease in GlyT2 expression and correspondingly in neurons LNX2 ablation results 
in an increase of the transporter.
LNX2 is required for PKC-mediated regulation of GlyT2 activity. Previous work showed that acti-
vation of PKC in glycinergic neurons results in an increased ubiquitination of GlyT2 and reduction of its expres-
sion and transport activity, suggesting that this may be a control mechanism of glycinergic neurotransmission 
strength10,11,21. PKC is a well-known regulator of neurotransmitter release in many synapse types in the CNS 
and its activation by phorbol esters has been classically used to dissect its essential role in the process of neuro-
transmitter release48–50. We reasoned that, since LNX2 appears to be a major controller of GlyT2 ubiquitination 
status, the effect of PKC activation in controlling GlyT2 function may require LNX2. To explore this, we ablated 
LNX2 expression in glycinergic neurons using shRNA as before and treated these cultures with PMA (Phorbol 
12-Myristate 13-Acetate), a known activator of PKC. While PKC activation in control neurons resulted in a reduc-
tion of GlyT2 levels by ~30% as expected (Fig. 4E, left), ablating LNX2 significantly blocked the effect of PMA 
(Fig. 4E, right; Fig. 4F shows quantification; n = 7 **p = 0,005). To confirm the impact of this modulation in the 
glycine transport activity of GlyT2, we measured [3H]-glycine transport uptake in primary neurons from brain-
stem and spinal cord in the same conditions. In agreement with expression experiments, transport by GlyT2 was 
significantly reduced (Fig. 4G; n = 6; ****p < 1 · 10−4) but no variation was observed in LNX2 depleted neurons. 
Taken together these experiments show that LNX2 is essential for the control of GlyT2 by PKC in glycinergic 
neurons, providing the missing molecular link between PKC activation and acceleration of GlyT2 ubiquitination.
Discussion
This study provides compelling novel evidence demonstrating that the RING-finger E3 ubiquitin ligases LNX1 
and LNX2 are functional regulators of the neuronal glycine transporter GlyT2. Our data from immunoprecipita-
tion, ubiquitination and glycine transport assays reveal that LNX1 and LNX2 interact with GlyT2 and ubiquiti-
nate a C-terminal cluster of lysines of this transporter to control its expression and activity. Using virally-delivered 
shRNAs we confirmed that endogenous LNX2 controls the expression of GlyT2 in glycinergic neurons, both 
constitutively and during PKC-mediated activation of GlyT2. Our work presents, to our knowledge, the first 
identification of an E3 ligase controlling GlyT2 ubiquitination, expression levels and activity.
ease of visualization. (E) COS7 cells were transiently transfected with GlyT2 or GlyT2-4KR in combination 
with pcDNA3 or LNX1-p80 and GlyT2 expression was measured by immunoblotting. Quantification of the 
effect of LNX1-p80 on GlyT2 and GlyT2-4KR expression was normalized against tubulin. (F) Quantification 
is shown normalized to the corrected signal in the control in each case with no LNX1-p80 co-transfection 
(indicated by dashed line). ***p = 1 · 10−4, n.s., not significantly different, using Kruskall-Wallis with Dunn’s 
post hoc test. n(GlyT2 control) = 10, n(GlyT2-p80) = 10, n(GlyT2-4KR) = 5, n(GlyT2-4KR-p80) = 5. Note 
that while LNX1-p80 induces a reduction of GlyT2 expression, GlyT2-4KR is highly protected in the same 
conditions. Effect of LNX1-p80 in wild type GlyT2 expression is shown here to ease comparison of the effects in 
GlyT2-4KR. FLAG immunobloting was used to confirm transfection of LNX1. (G) COS7 cells were transiently 
transfected as in (C) and glycine transport rates were measured using [3H]-glycine transport assays. Glycine 
transport shown is normalized against control conditions in each case. ****p < 1 · 10−4, n.s., not significantly 
different, using Kruskall-Wallis with Dunn’s post hoc test. Number of experiments in each case: n(GlyT2 
control) = 43, n(GlyT2-p80) = 27, n(GlyT2-4KR control) = 16, n(GlyT2-4KR-p80) = 16.
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Presynaptic GlyT2 activity is essential for sustaining glycinergic neurotransmission strength1–3 and its dys-
regulation is strongly associated with neurological disease5,51. Our identification of LNX1 and LNX2 as major 
controllers of GlyT2 suggests that these molecules may have a pathophysiological role in controlling glycinergic 
transmission by modulating presynaptic glycine recapture. LNX1/2 also interact with several other presynap-
tic proteins including CAST31, NUMB42,46, c-Src29, PKCα30, ERC1, ERC2 and LIPRIN-αs32. The interactional 
promiscuity of the LNX family suggests that LNX proteins may modulate presynaptic biology by coordinately 
tuning the expression of a diverse set of molecules. LNX1/2 present four PDZ domains with different recogni-
tion sequences52–54, which supports the idea that they can recognize and ubiquitinate many presynaptic inter-
actors29–32. Although speculative, a central role of LNX1/2 in coordinating presynaptic ubiquitination could act 
as a mechanism for the parallel adjustment of the function of several molecules controlling presynaptic biology. 
Such a mechanism would facilitate the choreographed modulation of the presynaptic molecular landscape, which 
could constitute a molecular mechanism to control on demand the strength of synaptic transmission.
On the other hand, given that LNX1/2 are multi-PDZ proteins, they may also act as molecular scaffolds to 
bring together their interacting partners to the same specific subcellular location30,52. LNX1/2 could coordinate 
Figure 3. Identification and characterization of LNX2 as interacting partner of GlyT2. (A) COS7 cells 
expressing GlyT2 and Myc-LNX2 were lysed and subjected to immunoprecipitation against GlyT2 and 
Myc. Immunoprecipitates were analyzed by immunoblotting for indicated proteins, showing that GlyT2 
coimmunoprecipitates LNX2 (middle lane). Correspondingly, LNX2 coimmunoprecipitate GlyT2 (right 
lane). (B) COS7 cells were transiently transfected with GlyT2 and with or without Myc-LNX2. GlyT2 was 
immunoprecipitated and ubiquitination of the transporter was assayed by immunoblotting with anti-ubiquitin 
antibody. Blots were probed against GlyT2 to normalize ubiquitination signal against the amount of GlyT2 
immunoprecipitated in each case to correct for GlyT2 protein expression. (C) Quantification of GlyT2 
ubiquitination normalized to the control (no transfection of Myc-LNX2). **p = 0.022, using Kolmogorov-
Smirnov test. n(control) = 6, n(LNX2) = 6. (D) COS7 cells were transiently transfected with GlyT2 or  
GlyT2-4KR in combination with pcDNA3 or Myc-LNX2 and GlyT2 expression was measured by 
immunoblotting. Quantification of the effect of LNX2 on GlyT2 and GlyT2-4KR expression was normalized 
against tubulin. (E) Quantification is shown normalized to the corrected signal in the control in each case with 
no LNX2 co-transfection (indicated by dashed line). ****p < 1 · 10−4, n.s., not significantly different, using 
Kruskall-Wallis with Dunn’s post hoc test. Number of experiments in each case: n(GlyT2 control) = 8, n(GlyT2-
LNX2) = 8, n(GlyT2-4KR) = 4, n(GlyT2-4KR-LNX2) = 4. Note the higher reduction of GlyT2 expression by 
LNX2 respect to that induced in GlyT2-4KR mutant. Myc immunobloting was used to confirm transfection 
of LNX2. (F) COS7 cells were transiently transfected with GlyT2 in combination with pcDNA3 or Myc-LNX2 
and glycine transport rates were measured using [3H]-Glycine transport assays as described inexperimental 
procedures. Glycine transport shown is normalized against control conditions. ****p < 1 · 10−4, n.s., not 
significantly different, using Mann-Whitney U test. n(control) = 27, n(LNX2) = 27.
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the presynaptic formation of multimolecular complexes of GlyT2 and other interacting partners28,31, facilitating 
the subcellular positioning and function of these proteins. GlyT2 has been previously shown to interact with 
several presynaptic proteins, including syntaxin116, Plasma Membrane Calcium ATPases PMCA2 and PMCA320 
and sodium/potassium ATPase subunits α3 (α3NKA) and β2 (β2NKA)19. It is possible that LNX1/2 may act as 
scaffold to facilitate the interaction of GlyT2 with these proteins, an idea supported by a recent proteomic study 
that found PMCA2 and β2NKA, known interactors of GlyT219,20, as interacting partners of LNX132.
A surprising fact in the LNX family is that, despite that LNXs mRNAs are easily detected28,46,55, LNX proteins 
are present at low levels in many adult tissues29,43,55. The low protein levels of LNX proteins may allow to dynam-
ically regulate their activity by simply generating novel protein through the existing mRNA. This putative mech-
anism would not be unique to LNX proteins, and in fact it has been already described that increased translation 
of existing transcripts can help to quickly synthesize newly required proteins to control short-term temporal 
adaptation mechanisms56. Even more, E3 ligase-substrate interactions are in many cases constitutive, and, in such 
cases, regulation is thought to occur at the level of E3 transcription/translation or degradation57. Such mechanis-
tic control of LNXs proteins presynaptically could be particularly relevant for neuronal function, as modulation of 
presynaptic ubiquitination has been shown to acutely regulate neurotransmitter release in mammalian neurons58.
Our shRNA experiments in glycinergic neurons reveal that LNX2 constitutively controls GlyT2 expression. 
However, it is essential to also understand in which conditions a glycinergic synapse may modulate this existing 
pathway to correspondingly control presynaptic glycine recapture by GlyT2. LNX1 domains PDZ2 and PDZ4 
Figure 4. Silencing of LNX2 in neurons causes upregulation of endogenous GlyT2 and abolish the PKC-
mediated regulation of GlyT2. (A) Relative mRNA levels of LNX1-p80 and LNX2 were determined by 
qPCR using Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping gene (arbitrary units). 
n(kidney) = 3, n(primary brainstem and spinal cord neuron cultures) = 3. (B) Neuronal cultures were infected 
with LNX2 shRNA and scrambled shRNA as control. After 12 DIV total RNA was extracted from cells and 
quantification of LNX2 mRNA was determined by qPCR. LNX2 mRNA in these conditions decreased by 
81.4 ± 11,8%. ****p < 1 · 10−4, n.s., not significantly different, using Kolmogorov-Smirnov test. n(control 
shRNA) = 14, n(LNX2 shRNA) = 14. (C) Cultured neurons were infected as in (B) and western blot analysis 
were performed using anti-GlyT2 antibodies. Tubulin was used as a loading control. (D) Quantification 
is shown normalized to the corrected signal in the control (scrambled shRNA) indicated by a dashed line. 
****p < 1 · 10−4, n.s., not significantly different, using Kolmogorov-Smirnov test. n(control shRNA) = 16, 
n(LNX2 shRNA) = 16. (E) Neuronal cultures infected with LNX2 shRNA or scrambled shRNA were treated 
with or without (vehicle) 1 µM PMA during 2 h and were subjected to western blot analysis using anti-GlyT2 
antibodies. Tubulin was used as protein loading control. Note that ablation of LNX2 impairs the effect of PMA 
on GlyT2 expression. (F) Quantification is shown normalized to the corrected signal in the control (vehicle) 
indicated by dashed line. **p = 0,005, n.s., not significantly different, using Two-way Anova with Sidak’s post 
hoc test. Number of experiments in each case: n(control shRNA + Veh) = 7, n(control shRNA + PMA) = 7, 
n(LNX2 shRNA + Veh) = 6, n(LNX2 shRNA + PMA) = 6. (G) In neuronal cultures infected and PMA treated 
as in E glycine transport rates were measured using [3H]-Glycine transport assays. Glycine transport shown 
is normalized against control conditions in each case. ****p < 1 · 10−4, n.s., not significantly different, using 
Two-way Anova with Sidak’s post hoc test. Number of experiments in each case: n(control shRNA + Veh) = 6, 
n(control shRNA + PMA) = 6, n(LNX2 shRNA + Veh) = 5, n(LNX2 shRNA + PMA) = 5.
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interact with Ca2+-dependent protein kinase C isoform α30, a known regulator of presynaptic short-term plas-
ticity48. Our data indicates that PKC activation accelerates ubiquitination of GlyT2 by LNX2, suggesting that this 
may be an additional mechanism that contributes to the effects of PKC activation in neurotransmitter release in 
a glycinergic synapse59. Given that other neurotransmitter transporters are also regulated by PKC60–64 and ubiq-
uitination61,65,66, it is possible that LNX2 may act as a controller of the activity of these transporters during PKC 
activation. Future work, however, will be required to dissect this possibility.
Ubiquitination is a major pathway that controls turnover of neuronal membrane proteins24. Although ubiquit-
ination is now considered a major regulatory pathway that controls GlyT2 function9,11,21, the molecular identity 
of the enzymes catalyzing GlyT2 ubiquitination has remained elusive. To our knowledge, the work presented 
here identifies the first E3-ubiquitin ligases acting on GlyT2. We discovered that the E3 ubiquitin ligases LNX1 
and LNX2 modulate the ubiquitination status of GlyT2, ubiquitinating its cytoplasmic C-terminal lysine cluster 
in a process that regulates the expression levels and transport activity of the transporter in neurons. Correct 
maintenance of glycine transport by GlyT2 is essential for human physiology, as GlyT2 is an essential regulator of 
glycinergic neurotransmission strength. Our identification of LNX1 and LNX2 as novel regulators of GlyT2 may 
have pathophysiological relevance on the biology of glycinergic neurotransmission and might help frame future 
investigations into the molecular basis of human disease states that are consequence of dysfunctional glycinergic 
neurotransmission, such as hyperekplexia and chronic pain.
Methods
Materials. Male Wistar rats were bred under standard conditions at the Centro de Biología Molecular Severo 
Ochoa (CBMSO) in accordance with procedures approved in the Directive 2010/63/EU of the European Union 
with approval of the Research Ethics Committee of the Universidad Autónoma de Madrid (Comité de Ética de 
la Investigación UAM, CEI-UAM). Antibodies against GlyT2 N-terminus were generated in house (rabbit and 
rat67,68) while the other primary antibodies used were: anti-c-Myc (Myc-Tag 9B11 Cell Signaling Tech.), anti-
FLAG M2 (Sigma-Aldrich, F3165), anti-HA (Sigma-Aldrich, clon 12CA5), anti-ubiquitin (P4D1, Santa Cruz), 
anti-α-tubulin (Sigma-Aldrich, T6074). All chemicals used were from Sigma Aldrich unless otherwise noticed. 
Neurobasal medium and B27 supplement were purchased from Invitrogen.
Plasmids, small hairping RNAs (shRNAs) and lentiviral particles generation. FLAG-tagged 
LNX1-p80 was a generous gift from Prof. Jane McGlade (University of Toronto), pClneoMyc mouse LNX1-p70 
and pClneoMyc mouse LNX2 were a gift from Yutaka Hata (Addgene plasmids #37009 and #37010, respectively) 
and pRK5-HA-Ubiquitin-WT was a gift from Ted Dawson (Addgene plasmid #17608). Generation of GlyT2-
4KR was described in previous work16,21. GlyT2 constructs are based on the longest rattus novergicus isoform 
of 799 aminoacids (Slc6a5-201, Ensembl transcript ID ENSRNOT00000041950.4). The shRNA sequence 
against LNX2 was designed by the The Genetic Perturbation Platform at the Broad Institute of Harvard and 
MIT (Massachusetts, USA) with the identification number TRCN0000040715. Since LNX1 and LNX2 present 
very short half-lives (see Supp. Fig. 1) and only last for 1–3 days after transfection, but the shRNA needs to be 
expressed for 11 days for efficient knock-down, it resulted technically challenging to match and re-express the 
wild-type LNX2 in the shLNX2 background to rescue the function as a control for the shRNA specificity. shRNA 
lentiviral particles were generated by transfection of HEK293T with the pLKO vectors containing shRNA, the 
packaging plasmid psPAX2 and the envelope plasmid pMD2G. The sequence of the shRNAs were as follows:
Scramble shRNA:
5′  -CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG-3′
LNX2 shRNA:
5′  -CCACTGATCAACATCGTCATT-3′
Cell growth and protein expression. COS7 cells (American Type Culture Collection) were grown at 
37 °C and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum. 
Transient expression was achieved using Turbofect Transfection Reagent (Fisher Scientific), according to the 
manufacturer’s protocol, and cells were then incubated for 24–48 h at 37 °C. Reproducible results were obtained 
with 80–90% confluent cells on 60-mm or 6-well plates, using 5 and 2 µg of total DNA, respectively. The ratio of 
DNA between GlyT2 and LNX1/2 variants was 1:4 to favor LNX1/2 overexpression.
Primary cultures of brainstem and spinal cord neurons and infection. Primary cultures of brain-
stem and spinal cord neurons were prepared as described previously19. Briefly, the brainstem and spinal cord of 
Wistar rat fetuses were obtained at the 16th day of gestation, and the tissue was then mechanically disaggregated 
in HBSS (Invitrogen) containing 0.25% trypsin (Invitrogen) and 4 mg/ml DNase (Sigma). Cells were plated at a 
density of 500,000 cells/well in 12 well multiwell plates (Falcon), and they were incubated for 4 h in DMEM con-
taining 10% FCS, 10 mM glucose, 10 mM sodium pyruvate, 0.5 mM glutamine, 0.05 mg/ml gentamicin, 0.01% 
streptomycin and 100 U/ml penicillin G. After 4 h this buffer was replaced with Neurobasal/B27 culture medium 
containing 0.5 mM glutamine (50:1 by volume: Invitrogen), and 2 days later cytosine arabinoside (1 µM) was 
added to inhibit further glial growth. Neuronal cultures were infected with lentiviruses at DIV 1. Lentivirus 
preparations were added directly to the culture medium and maintained for 24 h at 5% v/v. Neurons were then 
replaced in fresh medium and culture was continued until 12 DIV.
Quantitative Real-Time PCR (qPCR). Total RNA was extracted from cultured rat brainstem and spinal 
cord neurons following the TRI Reagent isolation protocol (Sigma-Aldrich).
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cDNA was synthetized using the iScript cDNA Synthesis kit (Bio-Rad) and qPCR was performed using Fast 
SYBR Green Master Mix (Thermofisher Scientific) following manufacture’s recommendations. Relative gene 
expression levels were quantified by the 2−∆∆Ct method using Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as housekeeping gene.
Primer sequences:
GAPDH:
5′  -TCCCATTCTTCCACCTTTGA-3′ 5′  -ATGTAGGCCATGAGGTCCAC-3′
LNX1:
5′  -TGGAGGCGGGCTGGTGA-3′ 5′  -TTCCTCAGGGGCAGGTCAAGA-3′
LNX2:
5′  -CCGTGTGCCAAGATGTAATG-3′ 5′  -GGATCCAGTTTCACCCTCAA-3′
Immunoprecipitation and western blotting. COS7 cells or primary cultures of brainstem and spinal 
cord were lysed for 30 min at room temperature (RT) at a concentration of 1.5 mg of protein/ml in TN buffer 
(25 mM Tris HCl and 150 mM NaCl [pH 7.4]) containing 0.25% Nonidet P-40 (NP-40) and protease inhibi-
tors (PIs: 0.4 mM phenylmethylsulfonyl fluoride (PMSF) and Sigma cocktail). After 15 min centrifugation in a 
microfuge to remove the cell debris, 4% of protein was separated to quantify total protein (T) and 5 μl of the pri-
mary antibody were added and left overnight at 4 °C using the following antibodies for immunoprecipitation: rat 
anti-GlyT2, anti-c-Myc or anti-FLAG M2. A negative control was also run in parallel in which no antibody was 
added. Subsequently, 50 μl of 50% protein G agarose beads (PGA; ABT beads Inc.) were added and incubated for 
45 min at 4 °C. The beads were collected by mild centrifugation and washed twice for 7 minutes with lysis buffer at 
RT. Finally, the beads were pelleted and the immunoprecipitated proteins were eluted in Laemmli buffer at 75 °C 
for 10 min, resolved in SDS/PAGE gels (7.5%), detected in Western blots by enhanced chemiluminescence (ECL). 
As previously reported, Western blot against GlyT2 obtained from COS7 cells lysates identified several bands 
corresponding to fully glycosylated functional transporter (100 KDa) and partially non-glycosylated intracellular 
forms (75 KDa) that tends to aggregate (150 KDa) due to having incomplete glycosylation18. In the main figures 
of this study we present the bands corresponding to the functional forms of GlyT2 (100 KDa) but supplementary 
figures show uncropped blots where all forms of the transporter can be visualized. In neurons, however, GlyT2 
only appears in the form of the functional transporter.
Ubiquitination assay. COS7 cells were transiently transfected with plasmids encoding wild-type or mutant 
GlyT2 proteins and with/without HA-tagged ubiquitin. 24–48 hours after transfection, cells were treated for 
3 hours at 37 °C with leupeptine 100 μM. Cells were washed twice with PBS at 4 °C, harvested using a buffer 
containing 50 mM Tris, 150 mM NaCl and 50 mM N-ethylmaleimide with protease inhibitors PMSF and Sigma 
protease inhibitor cocktail (Ubiquitination Buffer, UB) and analyzed for protein quantification. Equal amounts 
of protein samples were centrifuged and pellets were resuspended in 90 microliters of UB. 10 microliters of 10% 
sodium dodecyl sulphate (SDS) were added and incubated for 10 min at 95 °C to eliminate protein interactions. 
Then, 34 microliters of UB + 4% Triton and 1 ml of UB + 1%Triton X100 was added for 30 min at 4 °C and centri-
fuged. Lysates were precleared with 40 microliters of ProteinG-agarose for 30 min at 4 °C and then were incubated 
overnight with anti-GlyT2, coupled to ProteinG-agarose 1 h at room temperature followed by four washes with 
ice-cold lysis buffer and elution in 2x Laemmli sample buffer. Cell lysates were probed by Western blot analysis 
with specific antibodies against GlyT2, HA or ubiquitin (P4D1, Santa Cruz). We used anti alphaTubuline (sigma 
T-6074) as a loading control. Primary neurons infected with LNX2 shRNA or scrambled shRNA were subjected 
to the same procedure described for COS7 cells.
[3H]-Glycine transport assays. For assaying GlyT2 transport activity, cells were incubated in a solution 
with an isotopic dilution containing 2 μCi/ml [3H] glycine (1.6 TBq/mmol; PerkinElmer Life Sciences) in PBS, 
yielding a 10 μM final glycine concentration. To measure unspecific glycine accumulation (background), the 
transport assay was also performed in the presence of the GlyT2 antagonist ALX1393 (0.4 μM, IC50 = 50 nM). 
Transport was measured by subtracting the background glycine accumulation in COS7 cells or primary neurons 
and normalizing to the protein concentration and time of the reaction. Experiments in neurons were performed 
in the presence of the GlyT1 antagonist NFPS (10 μM) as these cultures present GlyT1 endogenous activity that 
would contaminate the measurements of GlyT2 transport activity. The reactions were terminated after 10 min by 
aspiration, followed by washing with HBS.
Densitometry, data analysis and statistics. The protein bands obtained by ECL (Bio-Rad) using 
film exposures in the linear range were imaged using a GS-900 calibrated imaging densitometer (Bio-Rad) and 
quantified using Image Lab Software (Bio-Rad). All statistical analyses were performed using GraphPad Prism 
(GraphPad Software). Kruskal-Wallis was used to compare multiple groups, with subsequent Dunn’s post-hoc 
test to determine the significant differences between samples. Kolmogorov-Smirnov and Mann-Whitney U tests 
were used to compare two separate groups. p values are denoted through the text as follows: *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001; p < 0.05 or lower values were considered significantly different when compared by 
one-way Kruskal-Wallis (Dunns’s posthoc test) or Kolmogorov-Smirnov and Mann-Whitney U tests. Thorough 
the text, the Box whisker plots represent median (line), mean (point), 25–75 percentile (box), 10–90 percentile 
(whisker), 1–99 percentile (X) and min - max (−) ranges.
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Data availability
The data generated and analyzed during this study are available from the corresponding authors on reasonable 
request. We also show uncropped original blots in the Supplementary Material.
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